Atluri Kavya, Aimlin Iris, Arora Shitij
Department of Bioinformatics, University of California, Los Angeles, CA 90095, USA.
Department of Internal Medicine, Montefiore Medical Center, New York, NY 10467, USA.
J Clin Med. 2022 Jul 1;11(13):3838. doi: 10.3390/jcm11133838.
The current pandemic due to the SARS-CoV-2 virus has caused irreparable damage globally. High importance is placed on defining current therapeutics for Coronavirus Disease 2019 (COVID-19). In this review, we discuss the evidence from pivotal trials that led to the approval of effective therapeutics in the treatment and prevention of COVID-19. We categorize them as effective outpatient and inpatient management strategies The review also attempts to contextualize the efficacy of therapeutics to the emerging variants. Vaccines, which remain the most effective prevention against hospitalization and deaths is not included in this review.
由严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)引发的当前大流行在全球造成了无法弥补的损害。确定2019冠状病毒病(COVID-19)的现有治疗方法至关重要。在本综述中,我们讨论了关键试验的证据,这些证据促成了治疗和预防COVID-19有效疗法的批准。我们将它们归类为有效的门诊和住院管理策略。本综述还试图将疗法的疗效与新出现的变体联系起来。本综述不包括疫苗,疫苗仍是预防住院和死亡最有效的手段。